Toggle light / dark theme

Excessive Cell Size Contributes to Senescence

In a new study [1], researchers have identified the reason why cells become defective when they grow too large and why protein creation fails when cells grow larger than their original healthy size, as is typically seen in aged and senescent cells.

They demonstrate that in enlarged yeast and human cells, RNA and protein biosynthesis does not scale in proportion to the additional cell size, which then leads to a dilution of the cytoplasm. This phenomenon is also present in senescent cells, which display similar traits to those of large cells.

The research team concludes that the maintenance of a cell type-specific DNA-to-cytoplasm ratio is essential for the majority of cellular functions, and when cellular growth changes this ratio, it encourages cells to become senescent.

These are the Russian-speaking Jewish Americans you never knew changed your life

Clockwise from top left: ‘Hammer and Silicon’ authors Daniel Satinsky, Sheila Puffer, and Daniel McCarthy (Courtesy Sheila Puffer); scientist Slava Epstein (Adam Glanzman/ Northeastern University); Vladimir Torchilin, director of pharmaceutical biotechnology and nanomedicine at Northeastern University; anti-aging researcher at Harvard, Vadim Gladyshev (YouTube screenshot).


From cancer research to designing systems powering the Eiffel Tower, the unsung scientists, inventors and entrepreneurs found in the new book ‘Hammer and Silicon’ make an impact.

British woman is first in the world to undergo gene therapy for most common form of blindness

A British woman has become the first person in the world to undergo gene therapy for the most common cause of sight loss.

Surgeons at the John Radcliffe Hospital in Oxford inserted a synthetic gene into the left eye of Janet Osborne, 80, who suffers from age-related macular degeneration (AMD).

Around 600,000 people in the UK are affected by AMD, which affects the central part of a patient’s vision with gaps or ‘smudges’, making everyday activities like reading and recognising faces difficult.

Liz Parrish : Gene therapy advancements | BioViva | People Unlimited

Liz talking about Rutgers, Integrated Health Systems, anti-aging vaccine(couple of years of gathering data), $75,000 single organ treatment, and potential for very affordable whole body treatment. Q&A at 32 minutes.


Liz Parrish | BioViva, presents at People Unlimited’s Ageless Education, about Gene Therapy Advancements.

The Ageless Education series brings in many of the leading figures in radical life extension to share their views on the most cutting edge strategies for living long enough to live forever.

For more info: http://www.peopleunlimitedinc.com

People Unlimited is an educational, lifestyle and social organization for people interested in living unlimited lifespans.

CRISPR gene editing makes stem cells ‘invisible’ to immune system

UC San Francisco scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally “invisible” to the immune system, a feat of biological engineering that, in laboratory studies, prevented rejection of stem cell transplants. Because these “universal” stem cells can be manufactured more efficiently than stem cells tailor-made for each patient—the individualized approach that dominated earlier efforts—they bring the promise of regenerative medicine a step closer to reality.

“Scientists often tout the therapeutic potential of pluripotent stem cells, which can mature into any adult tissue, but the immune system has been a major impediment to safe and effective stem cell therapies,” said Tobias Deuse, MD, the Julien I.E. Hoffman, MD, Endowed Chair in Cardiac Surgery at UCSF and lead author of the new study, published Feb. 18 in the journal Nature Biotechnology.

The immune system is unforgiving. It’s programmed to eradicate anything it perceives as alien, which protects the body against infectious agents and other invaders that could wreak havoc if given free rein. But this also means that transplanted organs, tissues or cells are seen as a potentially dangerous foreign incursion, which invariably provokes a vigorous immune response leading to transplant rejection. When this occurs, donor and recipient are said to be—in medical parlance—” histocompatibility mismatched.”

A Report from the Longevity Therapeutics Summit

The Longevity Therapeutics Summit was focused on therapeutics that target aging, rather than basic research or theory.


This was the first year for the Longevity Therapeutics Summit in San Francisco, California. Ably organized by Hanson Wade, with John Lewis, CEO of Oisín Biotechnologies, as program chair, the conference focused on senolytics for senescent cell clearance, big data and AI in finding new drugs (“in silico” testing), delivery systems for therapeutics like senolytics, TORC1 drugs, and biomarkers of aging, and the challenges of clinical trial development and FDA approval.

The conference featured a smorgasbord of cutting-edge longevity research, and, as the name implies, the general focus was on therapeutics that target aging, rather than basic research or theory.

Ned David, CEO of Unity Biotechnology, kicked off the conference with a talk about the company’s latest research on senolytics, which clear away senescent (“zombie”) cells, which secrete harmful chemicals that can cause neighboring cells to also become senescent. Unity has made the news recently with an extension request for its clinical trial of its first-in-class senolytics for osteoarthritis. Its preliminary Phase 1 clinical trial results were deemed “safe,” a major step in obtaining FDA approval, and the full results will be available later this year or in 2020.